Supplementary Figure 12 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
<p>Supplementary Figure 12. Disease-free survival and overall survival among patients with (A) stage I, (B) stage II, and (C) stage III NSCLC according to ATM expression by immunohistochemistry.</p>
Gorde:
Antzeko izenburuak
-
Supplementary Figure 1. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
nork: Biagio Ricciuti (14951247)
Argitaratua: (2025) -
Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
nork: Biagio Ricciuti (14951247)
Argitaratua: (2025) -
Supplementary Figure 11 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
nork: Biagio Ricciuti (14951247)
Argitaratua: (2025) -
Supplementary Figure 13 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
nork: Biagio Ricciuti (14951247)
Argitaratua: (2025) -
Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
nork: Biagio Ricciuti (14951247)
Argitaratua: (2025)